The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a prep
The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
대표청구항▼
1. A method for making a drug-coated angioplasty catheter, comprising: applying a solution of a lipophilic drug directly to a surface of a balloon wall of a balloon of an angioplasty catheter, anddrying the solution to form a coating of the lipophilic drug directly on the balloon wall to provide an
1. A method for making a drug-coated angioplasty catheter, comprising: applying a solution of a lipophilic drug directly to a surface of a balloon wall of a balloon of an angioplasty catheter, anddrying the solution to form a coating of the lipophilic drug directly on the balloon wall to provide an outermost surface over the balloon,wherein said solution comprises a solvent, said lipophilic drug, and a contrast agent, and said lipophilic drug is selected from azithromycin, roxithromycin, probucol, prostacyclins, corticoids, rapamycin, colchicine, paclitaxel, docetaxel, and 7-(2″,3″dihydroxypropyl oxycarbonyl)-paclitaxel. 2. The method of claim 1, wherein the lipophilic drug is paclitaxel. 3. The method of claim 2, wherein the solution consists of said solvent, paclitaxel, and said contrast agent. 4. The method of claim 1, wherein the solution consists of said solvent, said lipophilic drug, and said contrast agent. 5. The method of claim 1, also comprising processing said angioplasty catheter to be suitable for insertion into a patient with said coating providing said outermost surface. 6. The method of claim 1, wherein said solvent is ethanol. 7. A method of claim 1, wherein said solution consists of ethanol, paclitaxel, and a contrast agent, and said applying is by immersing said balloon surface into said solution. 8. The method of claim 1, wherein said contrast agent is selected from iodixanol, iopromide, iohexyl, iopamidol, gadolinium-DPTA, and Gd-DO3A-butrol. 9. The method of claim 8, wherein the lipophilic drug is paclitaxel. 10. The method of claim 8, wherein the lipophilic drug is rapamycin. 11. The method of claim 1, wherein said contrast agent is selected from iodixanol, iopromide, iohexyl, and iopamidol. 12. The method of claim 9, wherein the lipophilic drug is paclitaxel. 13. The method of claim 11, wherein the lipophilic drug is rapamycin. 14. A method for making a drug-coated angioplasty device, comprising: applying a solution of a lipophilic drug directly to a surface of a balloon of an angioplasty device, said solution comprising a solvent, said lipophilic drug, and a contrast agent, and drying the solution to form a coating of the lipophilic drug directly on the surface of said balloon to provide an outermost surface over said balloon,wherein said lipophilic drug is selected from azithromycin, roxithromycin, probucol, prostacyclins, corticoids, rapamycin, colchicine, paclitaxel, docetaxel, and 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel. 15. The method of claim 14, wherein the lipophilic drug is paclitaxel. 16. The method of claim 15, wherein the solution consists of said solvent, paclitaxel, and said contrast agent. 17. The method of claim 14, wherein the solution consists of said solvent, said lipophilic drug, and said contrast agent. 18. The method of claim 14, also comprising rendering said angioplasty device suitable for insertion into a patient with said coating providing said outermost surface. 19. The method of claim 14, wherein said surface is a balloon wall surface of the angioplasty device. 20. The method of claim 14, wherein said contrast agent is selected from iodixanol, iopromide, iohexyl, iopamidol, gadolinium-DPTA, and Gd-DO3A-butrol. 21. The method of claim 20, wherein the lipophilic drug is paclitaxel. 22. The method of claim 20, wherein the lipophilic drug is rapamycin. 23. The method of claim 14, wherein said contrast agent is selected from iodixanol, iopromide, iohexyl, and iopamidol. 24. The method of claim 23, wherein the lipophilic drug is paclitaxel. 25. The method of claim 23, wherein the lipophilic drug is rapamycin. 26. A method for making an angioplasty device useful for applying a lipophilic drug to a wall of a vascular vessel of a patient, the angioplasty device comprising a balloon having an outermost surface for contact with the wall of the vascular vessel, the method comprising: processing an angioplasty device so as to be suitable for insertion into a patient to perform an angioplasty, wherein the processed angioplasty device comprises a balloon having an outermost coating comprising a lipophilic drug, the outermost coating positioned on a portion of the balloon that contacts the wall of the vascular vessel upon conduct of an angioplasty procedure with the angioplasty device;wherein said processing includes applying an amount of a solution comprising a solvent, said lipophilic drug, and a contrast agent directly to the balloon to form said outermost coating, andwherein said lipophilic drug is selected from azithromycin, roxithromycin, probucol, prostacyclins, corticoids, rapamycin, colchicine, paclitaxel, docetaxel, and 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel. 27. The method of claim 26, wherein said lipophilic drug is paclitaxel. 28. The method of claim 26, wherein the solution consists of said solvent, paclitaxel, and said contrast agent. 29. The method of claim 26, wherein the solution consists of said solvent, said lipophilic drug, and said contrast agent. 30. The method of claim 26, wherein said contrast agent is selected from iodixanol, iopromide, iohexyl, iopamidol, gadolinium-DPTA, and Gd-DO3A-butrol. 31. The method of claim 30, wherein the lipophilic drug is paclitaxel. 32. The method of claim 30, wherein the lipophilic drug is rapamycin. 33. The method of claim 26, wherein said contrast agent is selected from iodixanol, iopromide, iohexyl, and iopamidol. 34. The method of claim 33, wherein the lipophilic drug is paclitaxel. 35. The method of claim 33, wherein the lipophilic drug is rapamycin. 36. A method for making a drug-coated angioplasty catheter, comprising: applying a solution of a lipophilic drug directly to a surface of a balloon wall of a balloon of the angioplasty catheter and drying the solution to form a coating comprising the lipophilic drug directly on the balloon wall to provide an outermost surface over the balloon,wherein said solution comprises a solvent, said lipophilic drug, and a contrast agent, and said lipophilic drug is selected from azithromycin, roxithromycin, probucol, prostacyclins, corticoids, rapamycin, colchicine, paclitaxel, docetaxel, and 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel. 37. A method for making a drug-coated angioplasty device, comprising: applying a solution of a lipophilic drug directly to a surface of a polymeric balloon wall of a balloon of an angioplasty device and drying the solution to form a coating of the lipophilic drug directly on the polymeric balloon wall to provide an outermost surface over the balloon,wherein said solution comprises a solvent, said lipophilic drug, and a contrast agent, and said lipophilic drug is selected from azithromycin, roxithromycin, probucol, prostacyclins, corticoids, rapamycin, colchicine, paclitaxel, docetaxel, and 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (201)
Stack Richard S. (Chapel Hill NC) Klopovic Zenaida P. (Durham NC), Absorbable stent.
Solomon Donald D. (Spring Valley OH) Byron M. Parke (Centerville OH), Anti-infective and antithrombogenic medical articles and method for their preparation.
Khan Mohammad A. (Sandy UT) Solomon Donald D. (Spring Valley OH) Byron Matthew P. (Centerville OH), Anti-infective and lubricious medical articles and method for their preparation.
Sawamoto Jiro (Fuji JPX) Takano Yoshihito (Fuji JPX) Ezaki Yuzo (Fuji JPX), Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material.
Bhat, Vinayak D.; Hossainy, Syed F. A.; Mirzaee, Daryush; Mandrusov, Evgenia; Sanders-Millare, Deborra; Guruwaiya, Judy A., Biocompatible carrier containing actinomycin D and a method of forming the same.
Cahalan Linda L. (Geleen NLX) Cahalan Patrick T. (Geleen NLX) Verhoeven Michel (Maastricht NLX) Hendriks Marc (Hoensbroek NLX) Fouache Benedicte (Maastricht NLX), Biocompatible medical article and method.
Buscemi Paul J. (Long Lake MN) Stejskal Elizabeth A. (St. Paul MN) Palme ; II Donald F. (Dayton MN) Wang Lixiao (St. Paul MN), Biodegradable drug delivery vascular stent.
Buscemi Paul J. (Long Lake MN) Stejskal Elizabeth A. (St. Paul MN) Palme ; II Donald F. (Dayton MN) Wang Lixiao (St. Paul MN), Biodegradable drug delivery vascular stent.
Bates, Brian L.; Ragheb, Anthony O.; Stewart, IV, Joseph M.; Bourdeau, William J.; Choules, Brian D.; Purdy, James D.; Fearnot, Neal E., Coated implantable medical device.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Ragheb, Anthony O.; Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Voorhees, III, William D.; Gershlick, Anthony H., Coated implantable medical device.
Ragheb, Anthony O.; Bates, Brian L.; Boatman, Scott E.; Burton, David G.; Hoffa, Michael C.; Schaeffer, Darin G.; Sturgeon, Jason S., Coated medical device.
Martin Ulrich (Mannheim DEX) Fischer Stephan (Polling DEX), Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof..
Greco Ralph S. (Princeton NJ) Harvey Richard A. (East Brunswick NJ) Trooskin Stanley Z. (North Brunswick NJ), Drug bonded prosthesis and process for producing same.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Dehdashtian Mark ; Saravia Maria Lilian ; Sakata Misuzu, Folding of catheter-mounted balloons to facilitate non-rotational radial expansion of intraluminal devices.
Everse Johannes (2613 Newcomb St. Lubbock TX 79430) Everse Kathleen E. (2613 Newcomb St. Lubbock TX 79430) Mercer Leo C. (4800 Alberta El Paso TX 79912), Immobilization of Streptokinase.
Matsuda Takehisa (Minou JPX) Nakayama Yasuhide (Minou JPX) Sugawara Takashi (Ikeda JPX), Immobilization of an anti-thrombogenic substance with a photo-reactive azide and a photo-crosslinking material.
Fox ; Jr. Charles L. (New York NY) Modak Shanta M. (River Edge NJ) Sampath Lester A. (Nyack NY), Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same.
Gruskin Elliott A. (East Norwalk CT) Lee Daniel R. (Madison CT) Brown Lloyd S. (Guilford CT), Infection-resistant surgical devices and methods of making them.
Reiley Mark A. ; Scholten Arie ; Talmadge Karen D., Inflatable device for use in surgical protocols relating to treatment of fractured or diseased bones.
Schwartz Robert S. (Rochester MN) Bresnahan John (Rochester MN) Bergman Rebecca M. (North Oaks MN) Coury Arthur J. (St. Paul MN) Lindell Elaine (Blaine MN) Hull Vincent W. (Fridley MN), Intravascular radially expandable stent.
Kaplan Aaron V. (Los Altos CA) Kermode James R. (Sunnyvale CA) Klein Enrique J. (Los Altos CA), Method and apparatus for sequentially performing multiple intraluminal procedures.
Domb Abraham J. (Efrat MD ILX) Shikani Alain H. (Ruxton MD), Method and device for inhibiting HIV, hepatitis B and other viruses and germs when using a catheter in a medical environ.
March Keith L. (Carmel IN) Hathaway David R. (Indianapolis IN) Wilensky Robert L. (Indianapolis IN), Method for delivery of smooth muscle cell inhibitors.
Leeb Ferenc (Villach ATX) Gazsi Lajos (Dusseldorf DEX), Method for filtering a digital value train with improved noise behavior, and circuit configuration for performing the me.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Method for making a drug delivery balloon catheter.
Szebeni,Janos; Alving,Carl R., Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules.
Haugwitz Rudiger D. (Bethesda MD) Zalkow Leon (Atlanta GA) Glinski Jan (Ridgefield CT) Suffness Mathew (Silver Spring MD) Deutsch Howard M. (Atlanta GA) Narayanan Venkatachala (Gaithersburg MD), Method of treating cancers sensitive to treatment with water soluble derivatives of taxol.
Frautschi Jack (Grand Prairie TX) Tingey Kevin (Salt Lake City UT), Methods and compositions for providing articles having improved biocompatability characteristics.
Cullinan George J. (Trafalgar IN) Singh Jai P. (Carmel IN) Wood Dan L. (Indianapolis IN), Methods for inhibiting vascular smooth muscle cell proliferation and restinosis.
Thulesius Olav (P.O. Box 24923 Kuwait 13110 KWX) Christenson Jan T. (P.O. Box 24923 Kuwait 13110 KWX), Methods for preventing thrombosis; and surgical implant having reduced platelet deposition characteristics.
Winters Suzanne (Salt Lake City UT) Solen Kenneth A. (Orem UT) Sanders Clifton G. (Salt Lake City UT) Mortensen J. D. (Sandy UT) Berry Gaylord (Salt Lake City UT), Multifunctional thrombo-resistant coatings and methods of manufacture.
Marchant Roger E. (Shaker Hts. OH), Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of b.
Burrell Robert E. (Sherwood Park CAX) McIntosh Catherine L. (Sherwood Park CAX) Morris Larry R. (Yarker CAX), Process of activating anti-microbial materials.
Desai Neil P. ; Tao Chunlin ; Yang Andrew ; Louie Leslie ; Zheng Tianli ; Yao Zhiwen ; Soon-Shiong Patrick ; Magdassi Shlomo,ILX, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Fitzgerald David J. ; Chaudhary Vijay Kumar,INX ; Pastan Ira H. ; Waldmann Thomas Alexander ; Queen Cary L., Recombinant antibody-toxin fusion protein.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Scott Neal A. (Atlanta GA) Hanson Stephen R. (Stone Mountain GA) King ; III Spencer B. (Atlanta GA) Harker Laurence A. (Atlanta GA), Stent sheath for local drug delivery.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
Klopp Rainer,DEX ; Niemer Wolfgang,DEX ; Schippel Wolfgang,DEX ; Krause Werner,DEX, Use of prostacyclin derivatives to prevent or to treat disorders of the microcirculatory system when x-ray, NMR or ultra.
Michal, Eugene T.; Lerner, Daniel J.; Pollman, Matthew J., Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens.
Michal, Eugene T.; Lerner, Daniel J.; Pollman, Matthew J., Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens.
Michal, Eugene T.; Lerner, Daniel J.; Pollman, Matthew J., Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.